United Therapeutics CEO Martine Rothblatt Exercises and Sells $5.3M in Common Stock Under 10b5-1 Plan
UNITED THERAPEUTICS Corp
Subscribe to track UTHR
Premium users can add ticker alerts and receive realtime notification updates.
Filing Summary
# Insider Trade Alert: UNITED THERAPEUTICS Corp ($UTHR)
**Insider:** ROTHBLATT MARTINE A (Chairperson & CEO)
**Filing Date:** 2026-10-22 | **Transaction Date:** 2026-10-21
### Transaction Summary
- **Type:** Option Exercise & Sale (Rule 10b5-1)
- **Shares Sold:** 9,500 shares
- **Average Sale Price:** ~$560.07
- **Gross Proceeds:** ~$5,320,675
- **Exercise Price:** $117.76 (Cost: $1,118,720)
- **Shares Retained in Trust:** 324,443
### Trading Context
- Routine transaction executed pursuant to a Rule 10b5-1 plan established on November 7, 2025.
- The insider continues to maintain substantial direct and indirect beneficial ownership across family trusts exceeding 668,000 shares, alongside 185,910 remaining options in the trust.
Comprehensive Analysis
Executive Summary
On October 21, 2026, Dr. Martine A. Rothblatt, Chairperson & CEO of United Therapeutics Corp ($UTHR), executed an option exercise and sale covering 9,500 shares of common stock. The transactions generated aggregate gross proceeds of approximately $5.32 million at a weighted average price of approximately $560.07 per share. The options were exercised at an exercise price of $117.76 per share.
Transaction Details
- Derivative Exercise: 9,500 stock options exercised at $117.76 per share (options originally set to expire on March 15, 2027).
- Open Market Sales: 9,500 shares disposed of across 14 tranches at prices ranging between $552.05 and $566.43, for a combined total consideration of $5,320,674.75.
- Pre-Arranged Plan: All transactions were conducted pursuant to a pre-established Rule 10b5-1 trading plan adopted on November 7, 2025.
- Post-Transaction Holdings: The trust executing the trade retained 324,443 shares of common stock and 185,910 options. Across direct ownership and various family trusts, Dr. Rothblatt continues to beneficially hold over 668,000 shares of common stock.
Market Impact & Significance
This filing reflects scheduled option monetizations under a pre-established 10b5-1 trading plan ahead of the March 2027 option expiration. Given the automated nature of the plan and the executive's significant continuing equity alignment, the trading significance is categorized as Medium.
Get Real-Time Alerts
Join our community to receive instant notifications when high-significance filings are published
Important Disclaimer
This content is drawn from public SEC filings and may contain errors. It is for informational purposes only and is not investment, legal, or tax advice.
Nothing here is a recommendation to buy, sell, or hold any security. Do your own due diligence.